Resurfacing an August move: Marico's Q1 revenue rose 23%; raised Plix maker Satiya stake to 60%

Marico had reported Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year on year, while net profit grew 8.2% to Rs 513 crore, in an August 2025 announcement resurfacing now. India revenue rose 27.2%, and the company increased its fully diluted stake in Satiya Nutraceuticals, owner of Plix, to 60%.

— Filed Sun, 16 Aug, 2026, 23:18 IST · First seen Sun, 16 Aug, 2026, 23:18 IST · Source Financial Express · BrandWagon

What happened

Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by 27.2% India revenue growth. The company increased its stake in Plix maker

Key facts

  • Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income: Rs 3,315 crore
  • Other income: Rs 56 crore
  • Total expenses: Rs 2,659 crore versus Rs 2,075 crore
  • India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
  • International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
  • India segment PBT: Rs 469 crore
  • International segment PBT: Rs 213 crore
  • Marico increased Satiya Nutraceuticals stake to 60% fully diluted

Why this matters

Raising Satiya Nutraceuticals ownership to 60% gives Marico control of Plix and strengthens its position in high-growth health and wellness adjacencies.

What to watch

  • Whether India revenue growth remains above the low-to-mid teens after the Q1 base effect.
  • Gross-margin and EBITDA-margin trends versus revenue growth, especially amid copra, edible-oil and packaging-cost movements.
  • Plix sales growth, repeat-purchase metrics, offline expansion and contribution to consolidated profitability.
  • Any further change in Marico's stake, governance control or earn-out obligations related to Satiya Nutraceuticals.
  • Competitive intensity and discounting in nutrition, supplements and digital-first wellness brands.
  • Rural demand recovery and volume growth in Marico's core India portfolio.
  • Increase Plix distribution through Marico's general-trade, modern-trade and e-commerce network while retaining its digital-native brand positioning.
  • Allocate more marketing and innovation spending to health, wellness, protein, beauty-from-within and adjacent premium categories.
  • Seek procurement, supply-chain and back-end synergies from majority ownership of Satiya Nutraceuticals.
  • Use strong domestic growth to support selective portfolio expansion while monitoring profitability discipline.